Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Imunon, Inc. Secures $2.5 Million in Series A Funding
PUBLIC · IMNNSep 28, 2026
Amount Raised
$2.5 Million
Round Type
Series A
LawrencevilleBiotechnology
Investors
Streeterville Capital, Llc
Description
On September 28, 2026, Imunon, Inc. announced the completion of a funding round with an investor, Streeterville Capital, LLC. The deal included the issuance of 250 shares of Series A Preferred Stock and two secured promissory notes totaling $7.72 million. This funding is intended to support the company's ongoing research and development efforts.
Company Information
Company
IMUNON
Location
Lawrenceville, New Jersey, United States
About
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
Fundz sees it the moment IMUNON raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
LawrencevilleBiotechnology